Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1313-1321

  Stoch, S Aubrey ^a   Gargano, Cynthia ^a   Valentine, Jack ^a   Braun, Matthew P ^a   Murphy, M Gail ^a   Fedgchin, Margaret ^a   Majumdar, Anup ^a   Pequignot, Edward ^b   Gottesdiener, Keith M ^a   Petty, Kevin J ^a   Panebianco, Deborah ^a   Dean, Dennis ^a   Kraft, Walter K ^b   Greenberg, Howard E ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Clinilabs Inc   (United States)

Author keywords

Aprepitant; CYP3A4; Midazolam; Nausea vomiting; Ondansetron; Pharmacokinetics

Indexed keywords

APREPITANT; CARBON 13; CYTOCHROME P450 3A4; DEXAMETHASONE; MIDAZOLAM; NITROGEN 15; ONDANSETRON; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIEMETICS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDAZOLAM; MORPHOLINES; ONDANSETRON;

EID: 79959621590     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1421-y     Document Type: Article

References (27)

1. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947
2. Multinational Association for Supportive Care in Cancer (MAS-CC) (2008) Perugia international cancer conference VII: consensus committee on antiemetic therapy. March 2008 update. Available at http://www.mascc.org/index.php?load= pro-study-groups&page-id=86. Accessed 21 April 2009
3. National Comprehensive Cancer Network (NCCN) (2007) Clinical practice guidelines in oncology antiemesis - version 1. Available 3 at http://www.mascc.org/media/Resource-centers/MASCC-Guidelines-Update.pdf. Accessed 13 April 2009
4. EMEND® (aprepitant) capsules [package insert] (2008) Merck & Co. Inc., Whitehouse Station, NJ
5. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215-223 (Pubitemid 38233818)
6. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150-156 (Pubitemid 36951812)
7. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407-1419 (Pubitemid 36677284)
8. Li S, Pequignot E, Panebianco D, Lupinacci P, Majumdar A, Rosen L, Ahmed T, Royalty JE, Rushmore TH, Murphy MG, Petty KJ (2006) Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. J Clin Pharmacol 46:792-801 (Pubitemid 43882803)
9. Shah A, Hunt TL, Gallagher SC, Cullen MT (2005) Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 21:595-601 (Pubitemid 40676112)
10. Jang GR, Maurel PJP (2000) Rifampin, dexamethasone, and omeprazole. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic drug interactions. Lippincott, Williams & Wilkins, Philadelphia, pp 691-705
11. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J Clin Invest 3:688-697 (Pubitemid 19061193)
12. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356-366
13. Chiou WL, Jeong HY, Wu TC, Ma C (2001) Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther 70:305-310 (Pubitemid 33022470)
14. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR (1999) Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66:224-231 (Pubitemid 29451753)
15. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502 (Pubitemid 26193889)
16. Nakajima M, Suzuki T, Sasaki T, Yokoi T, Hosoyamada A, Yamamoto T, Kuroiwa Y (1999) Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. Ther Drug Monit 21:507-513 (Pubitemid 29468316)
17. Palmer JL, Barrington P, Collyer S (2000) An evaluation of the effects of oral dexamethasone 2 mg and 5 mg once daily for 7 days on CYP3A4 activity [abstract]. Br J Clin Pharmacol 49:504P-505P
18. Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326 (Pubitemid 33022472)
19. Van Dort ME, Ciliax BJ, Gildersleeve DL, Sherman PS, Rosenspire KC, Young AB, Junck L, Wieland DM (1988) Radioiodinated benzodiazapines: agents for mapping glial tumors. J Med Chem 31:2081-2086
20. Walser A, Benjamin LE, Flynn T, Schwartz R, Fryer RI (1978) Quinazolines and 1,4-benzodiazapines. Synthesis and reactions of imidazobenzodiazapines. J Org Chem 43:936-944 (Pubitemid 8337008)
21. Walser A, Fryer RI (1983) Quinazolines and 1,4-benzodiazapines. XCIII. Synthesis of imidazobenzodiazapines from nitroximes. J Heterocycl Chem 20:551-558 (Pubitemid 13074593)
22. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036 (Pubitemid 18075638)
23. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24 (Pubitemid 36776172)
24. Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall SD (2001) The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharm Ther 70:317-326
25. Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharm 40:523-530 (Pubitemid 26005556)
26. Palmer JL, Barrington P, Colliyer S (1998) An evaluation of the effects of oral dexamethasone 2 mg and 5 mg once daily for 7 days on CYP3A4 activity. Br J Clin Pharmacol 64:133-143
27. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin [pharmacokinetics and drug disposition]. Clin Pharm Ther 64:133-143 (Pubitemid 28423848)